CompletedPhase 2

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis

United States50 participantsStarted 2016-03-08

Plain-language summary

To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Botulinum toxin to the palmar area within 9 months of baseline visit
✕. Iontophoresis within 30 days of baseline visit
✕. Palmar thermolysis, sympathectomy or surgical procedures of the palmar area any time in the past
✕. Serotonergic agonist within 30 days of baseline visit
✕. Any topical prescription treatment for hyperhidrosis within 30 days of baseline visit
✕. Any over-the-counter topical antiperspirant/deodorant within 7 days of baseline visit

What they're measuring

Number of Treatment Emergent Adverse Events by Severity

Timeframe: Baseline visit-Day 42 End of Participation

Trial details

NCT IDNCT02682238

SponsorBotanix Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-07-14

Results submitted2022-12-15

View on ClinicalTrials.gov More Hyperhidrosis trials